Pfizer Opts for Access Over Exclusivity in Antibodies

For its biggest antibody deal to date, Pfizer choose Medarex, which insists on non-exclusive agreements, leaving the biotech free to work with other partners on any given target. In doing so, Pfizer reckoned that the potential for competition with respect to a particular target was outweighed by the greater access to targets which Medarex's deal model provides.